Cyclophosphamide, Alvocidib (Flavopiridol), and Rituximab, a Novel Feasible Chemoimmunotherapy Regimen for Patients with High-Risk Chronic Lymphocytic Leukemia

Alvocidib has demonstrated efficacy in high-risk chronic lymphocytic leukemia (CLL) patients. In this phase I study, we combined cyclophosphamide, alvocidib and rituximab (CAR) in a schema designed to mitigate tumor lysis syndrome (TLS) seen previously with alvocidib. Nine nucleoside analog-naïve, h...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Stephens, Deborah M., Ruppert, Amy S., Maddocks, Kami, Andritsos, Leslie, Baiocchi, Robert, Jones, Jeffrey, Johnson, Amy J., Smith, Lisa L., Zhao, Yuan, Ling, Yonghua, Li, Junan, Phelps, Mitch A., Grever, Michael R., Byrd, John C., Flynn, Joseph M.
Formato: Artigo
Idioma:Inglês
Publicado em: 2013
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3934299/
https://ncbi.nlm.nih.gov/pubmed/23867058
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.leukres.2013.06.006
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados